Telithromycin: the first of the ketolides

Area of Science:

• Pharmacology
• Microbiology
• Medicinal Chemistry

Background:

• Telithromycin represents a new class of antibiotics, the ketolides, developed through modifications of the macrolide structure.
• It exhibits enhanced activity against key respiratory pathogens, including drug-resistant Streptococcus pneumoniae.

Purpose of the Study:

• To comprehensively review the chemistry, antimicrobial spectrum, pharmacology, clinical effectiveness, and safety profile of telithromycin.
• To evaluate its potential role in treating community-acquired respiratory tract infections.

Main Methods:

• Literature search of MEDLINE, PubMed, scientific conference abstracts, and regulatory meeting minutes from 1966 to December 2000.
• Review of medicinal chemistry, in vitro, animal, and human trial data.

Main Results:

• Telithromycin demonstrates potent activity against macrolide-resistant Streptococcus pneumoniae due to unique ribosomal binding.
• Pharmacokinetics support once-daily dosing with good lung tissue and phagocytic cell distribution.
• Clinical efficacy is comparable to existing agents, but gastrointestinal adverse events are more frequent. Potential QTc prolongation and liver function test elevations require consideration.

Conclusions:

• Telithromycin presents advantages over traditional macrolides/azalides for infections involving macrolide-resistant pathogens.
• Further investigation is required to clarify its efficacy against Haemophilus influenzae, drug interaction potential, and safety in specific patient populations.